369 related articles for article (PubMed ID: 17095337)
1. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
Sontag MK; Corey M; Hokanson JE; Marshall JA; Sommer SS; Zerbe GO; Accurso FJ
J Pediatr; 2006 Nov; 149(5):650-657. PubMed ID: 17095337
[TBL] [Abstract][Full Text] [Related]
2. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
6. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
7. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
Ren CL; Desai H; Platt M; Dixon M
Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969
[TBL] [Abstract][Full Text] [Related]
9. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
10. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.
Farrell PM; Kosorok MR; Laxova A; Shen G; Koscik RE; Bruns WT; Splaingard M; Mischler EH
N Engl J Med; 1997 Oct; 337(14):963-9. PubMed ID: 9395429
[TBL] [Abstract][Full Text] [Related]
11. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis.
Farrell PM; Koscik RE
Pediatrics; 1996 Apr; 97(4):524-8. PubMed ID: 8632940
[TBL] [Abstract][Full Text] [Related]
12. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.
Keiles S; Koepke R; Parad R; Kharrazi M;
J Cyst Fibros; 2012 May; 11(3):257-60. PubMed ID: 22209734
[TBL] [Abstract][Full Text] [Related]
13. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
14. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
15. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
[TBL] [Abstract][Full Text] [Related]
16. [Mucoviscidosis screening with immunoreactive trypsin].
Eber E; Ellemunter H; Engele H; Götz M; Grünberger W; Haas J; Janisch H; Leodolter S; Litscher H; Müller G
Wien Klin Wochenschr; 1992; 104(22):681-5. PubMed ID: 1475973
[TBL] [Abstract][Full Text] [Related]
17. Thirty-years of screening for cystic fibrosis in East Anglia.
Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
[TBL] [Abstract][Full Text] [Related]
18. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
19. [Mucoviscidosis screening of newborn infants in the Dresden district. Results from 1 June 1996 to 31 March 2000].
Wunderlich P; Stopsack M; Paul KD; Rösen-Wolff A
Dtsch Med Wochenschr; 2000 Nov; 125(45):1356-60. PubMed ID: 11109423
[TBL] [Abstract][Full Text] [Related]
20. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]